LabCorp Presents New Findings on HIV-1 and HCV Antiviral Drug Resistance at the 2015 Conference on Retroviruses and Opportunistic Infections

State of the art genetic and cell-based assays enable comprehensive characterization of resistance to new drugs and new drug classes BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 12, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that Monogram Biosciences,

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 11, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of March 12, 2015 to September 11, 2015 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp Contributes to Clinical Research Collaborations Directed at Advancing Treatment of Breast Cancer and Viral Hepatitis

Studies Promote Personalized Medicine and Advance Public Health Initiatives BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 4, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today highlighted clinical research efforts in oncology and viral hepatitis that demonstrate its

LabCorp is Scheduled to Present at the Barclays Capital 2015 Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 3, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the Barclays Capital 2015 Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 10, 2015 at 8:30 AM (Eastern

Laboratory Corporation of America® Holdings Announces 2014 Fourth Quarter and Full Year Results and Provides 2015 Guidance

Strong Q4 volume drives sales of $1.5 billion Diluted Q4 EPS of $1.39 ; Adjusted Q4 EPS of $1.65 Q4 Operating Cash Flow of approximately $214 million Q4 Free Cash Flow of approximately $167 million Announces Project LaunchPad, its enterprise-wide business process improvement initiative 2015

LabCorp Completes Acquisition of Covance

Combination Creates Leading Healthcare Diagnostics Company & End-to-End Solutions for Drug Development and Commercialization BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 19, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the completion of its acquisition of

LabCorp Launches New Patient-Centric Diabetes Report

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 10, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of a new Diabetes Patient Education report for type 2 diabetes patients that aligns with the American Diabetes Association (Association)

LabCorp Prices $500,000,000 in 2.625% Senior Notes Due 2020, $500,000,000 in 3.200% Senior Notes Due 2022, $1,000,000,000 in 3.600% Senior Notes Due 2025 and $900,000,000 in 4.700% Senior Notes Due 2045

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that it has priced its offering of $2.9 billion in senior notes. The offering consists of four tranches: $500,000,000 aggregate principal amount of 2.625% Senior

LabCorp Announces Proposed Sale of Senior Notes

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in four tranches with maturities of 5,7,10 and 30

LabCorp is Scheduled to Present at the 33rd Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 6, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the 33 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.